Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies-Reference-Cited by-同舟云学术

Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies

Published:2017-08-28 Issue:6 Volume:17 Page:573-579
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Castellano Daniel¹,Maroto José Pablo²,Espinosa Enrique³,Grande Enrique⁴,Bolós M Victoria⁵,Llinares Julia⁵,Esteban Emilio⁶,González del Alba Aranzazu⁷,Climent Miguel Angel⁸,Arranz Jose Angel⁹,Méndez Mª José¹⁰,Fernández Parra Eva¹¹,Antón-Aparicio Luis¹²,Bayona Cristina¹³,Gallegos Isabel¹⁴,Gallardo Enrique¹⁵,Samaniego Luz¹⁶,García Donas Jesús¹⁷

Affiliation:

1. Hospital Universitario 12 de Octubre, Madrid, Spain

2. Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

3. Hospital Universitario La Paz, Madrid, Spain

4. Ramón y Cajal University Hospital, Madrid, Spain

5. Pfizer, Madrid, Spain

6. General University Hospital of Asturias, Asturias, Spain

7. Hospital Universitario Son Espases, Palma de Mallorca, Spain

8. Instituto Valenciano de Oncología, Valencia, Spain

9. Hospital General Universitario Gregorio Marañón, Madrid, Spain

10. Medical Oncology, Hospital Universitario Reina Sofia, Córdoba, Spain

11. Hospital de Valme, Sevilla, Spain